EG-018

EG-018 is a carbazole-based synthetic cannabinoid that has been sold online as a designer drug.[1][2][3][4][5] It acts as a partial agonist of the CB1 and CB2 receptor, with reasonably high binding affinity, but low efficacy in terms of inducing a signaling response.[6]

EG-018
Legal status
Legal status
Identifiers
IUPAC name
  • Naphthalen-1-yl-(9-pentylcarbazol-3-yl)methanone
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC28H25NO
Molar mass391.514 g·mol−1
3D model (JSmol)
SMILES
  • CCCCCN1C2=C(C=C(C=C2)C(=O)C3=CC=CC4=CC=CC=C43)C5=CC=CC=C51
InChI
  • InChI=1S/C28H25NO/c1-2-3-8-18-29-26-15-7-6-13-23(26)25-19-21(16-17-27(25)29)28(30)24-14-9-11-20-10-4-5-12-22(20)24/h4-7,9-17,19H,2-3,8,18H2,1H3
  • Key:FJMMDJDPNLZYLA-UHFFFAOYSA-N

EG-018 is a controlled substance in Japan.[7]

See also

References
  1. "EG 018". www.caymanchem.com.
  2. Mogler L, Franz F, Wilde M, Huppertz LM, Halter S, Angerer V, et al. (September 2018). "Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples". Drug Testing and Analysis. 10 (9): 1417–1429. doi:10.1002/dta.2398. PMID 29726116.
  3. Banister SD, Connor M (August 2018). "The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution". New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. Springer International Publishing. pp. 191–226. doi:10.1007/164_2018_144. ISBN 978-3-030-10561-7. PMID 30105473 – via Springer Link.
  4. Gaunitz F, Dahm P, Mogler L, Thomas A, Thevis M, Mercer-Chalmers-Bender K (June 2019). "In vitro metabolic profiling of synthetic cannabinoids by pooled human liver microsomes, cytochrome P450 isoenzymes, and Cunninghamella elegans and their detection in urine samples". Analytical and Bioanalytical Chemistry. 411 (16): 3561–3579. doi:10.1007/s00216-019-01837-8. PMID 31183523. S2CID 184487406.
  5. Diao X, Carlier J, Zhu M, Huestis MA (July 2018). "Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry". Forensic Toxicology. 36 (2): 304–312. doi:10.1007/s11419-018-0404-2. ISSN 1860-8973. S2CID 44196013.
  6. Gamage TF, Barrus DG, Kevin RC, Finlay DB, Lefever TW, Patel PR, et al. (June 2020). "In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018". Pharmacology, Biochemistry, and Behavior. 193: 172918. doi:10.1016/j.pbb.2020.172918. PMC 7239729. PMID 32247816.
  7. "指定薬物を指定する省令が公布されました｜厚生労働省". www.mhlw.go.jp (in Japanese). Ministry of Health, Labour and Welfare.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.